Roche has announced results from its Phase IIb PADOVA study evaluating prasinezumab in patients with early-stage Parkinson’s disease. While the primary endpoint of time to confirmed motor progression did not reach statistical significance, the drug demonstrated promising trends in several secondary and exploratory endpoints.
 
The study, which enrolled 586 patients, assessed the efficacy and safety of prasinezumab over 18 months. While the primary endpoint was not met, a pre-specified analysis revealed a more pronounced effect in patients treated with levodopa, a common Parkinson’s medication.
 
“Parkinson’s is complex and devastating with no disease modifying treatment options available for the millions of people impacted,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “We believe the consistent efficacy trends from the Phase IIb study of prasinezumab merit further exploration. We will continue our close collaboration with the Parkinson’s community as we further evaluate the data to determine next steps.”
 
Roche plans to present full results from the PADOVA study at an upcoming medical meeting.